Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2014-06-11

Clinical Trial Update: Efficacy and Safety of 4 Weeks of Treatment With Inhaled BI 1744 CL in Patients With Asthma [Phase 2]

View source ↗

Summary

Phase 2 study evaluating 4 weeks of inhaled BI 1744 CL in asthma patients reported efficacy and safety outcomes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • BI 1744 CL

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Asthma | Phase 2 | Status: COMPLETED | Results posted: 2014-06-11